12-17 days following finalized histopathology report.
Specimen
Fine‑Needle Aspirate (FNA) Samples: FNA Slides ≥2 highly cellular unstained or stained slides + 1 Diffquick FNA Liquid ≥0.5 mL in sterile vial/tube with no additives.
Bone Tumor: Non‑decalcified sample.
Test Description
SearchLight DNA™ is an add‑on test to any biopsy or cytology where cancer is suspected or diagnosed. This test provides precision diagnostic, prognostic, and therapeutic guidance for multiple types of cancers.
This canine cancer genomic panel identifies mutations in 120 relevant cancer genes and provides insights into cancer’s origin, behavior, and the optimal approach for treatment.
Report includes:
• Information about mutations in 120 cancer genes including diagnostic, prognostic, and therapeutic biomarker associations with supporting evidence from peer‑reviewed literature, clinical consensus, and inference from human FDA guidance.
• Pharmacogenomic marker (MDR1) mutation status.
• A list of targeted therapeutic drug(s) if the patient’s tumor mutations are a match for an existing drug.
• Information on clinical trials by tumor type curated from public databases and individual academic centers by Vidium Animal Health.
To order SearchLight DNA™, please contact customer service.
Note: SearchLight DNA™ can be added to a biopsy or cytology performed by a board‑certified pathologist where neoplasia has been diagnosed or suspected.